Dyslipidemia is a definite risk factor of cardiovascular disease (CVD).Despite the increased prevalence of dyslipidemia in the elderly, consideration about side effect and safety of lipid therapy persists in this group.We discuss characteristics of dyslipidemia, change of pharmacokinetics and pharmacodynamics in the elderly, and evaluate safety of statins on liver, muscle, kidney, nerve system and tumor in the elderly by the evidence of a series of clinical trials.